Inventor · disambiguated record
Hanlan Liu
Also filed as: LIU HANLAN
8 granted patents·13 pending applications·91 citations·filing 1998–2023
86Inventor score
Top patents by PatentIndex Score
21 records- 0190US9139580B2Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2013·Granted Sep 22, 2015·14 cites·1 claims
- 0287US9126993B2Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2014·Granted Sep 8, 2015·9 cites·1 claims
- 0386US6761912B2Composition for increasing bone densityPHARMAVITE LLC·Filed 2001·Granted Jul 13, 2004·25 cites·16 claims
- 0477US12465586B2Inhibitors of glucosylceramide synthaseGENZYME CORP·Filed 2022·Granted Nov 11, 2025·0 cites·7 claims
- 0572US2021261557A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2021·Application pending·0 cites
- 0671US2021393590A1Inhibitors of glucosylceramide synthaseGENZYME CORP·Filed 2021·Application pending·0 cites
- 0769US6436446B1Composition for increasing bone densityPHARMAVITE LLC·Filed 1999·Granted Aug 20, 2002·34 cites·9 claims
- 0869US2021369672A1Inhibitors of glucosylceramide synthaseGENZYME CORP·Filed 2021·Application pending·0 cites
- 0967US11458119B2Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthaseLIU HANLAN·Filed 2010·Granted Oct 4, 2022·1 cites·25 claims
- 1065US2024034738A1Solid state forms of substituted pyrazolopyrimidines and uses thereofKSQ THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1164US11718624B2Solid state forms of substituted pyrazolopyrimidines and uses thereofKSQ THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·0 cites·27 claims
- 1264US2020048266A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2019·Application pending·0 cites
- 1361US2025002453A1Pharmaceutically acceptable salt of eliglustat and crystal form thereofSPEROGENIX SHANGHAI MEDTECH CO LTD·Filed 2022·Application pending·0 cites
- 1461US2024423952A1Compositions and methods for treating congenital disordersIBAGEN PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1560US2016120842A1Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthaseGENZYME CORP·Filed 2016·Application pending·0 cites
- 1657US2025161306A1Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumorsKSQ THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1753US2016207933A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2015·Application pending·0 cites
- 1853US2023065636A1Compositions of substituted pyrazolopyrimidines and uses thereofKSQ THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1951US2023277533A1Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitorsKSQ THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2051US2025346587A1Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereofSPEROGENIX THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 2134US6829540B1Drug discovery using multiple membrane mimetic affinitiesPURDUE RESEARCH FOUNDATION·Filed 1998·Granted Dec 7, 2004·8 cites·30 claims
Join the waitlist — get patent alerts
Get an alert when Hanlan Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →